- Neuropeptide / Neuroprotection Research
Semax
- Compound type
Synthetic ACTH-fragment-derived heptapeptide
- Research status
- Scientific overview
Overview
Semax is a synthetic heptapeptide derived from a short ACTH-related sequence and modified for greater stability. Research has examined neurotrophic factors such as BDNF and NGF, dopaminergic and serotonergic signaling, oxidative stress, neuroplasticity, learning, and models of cerebral ischemia. Much of the human clinical literature originates from Russia and nearby regions. Apex should distinguish experimental neuroprotection findings from established U.S. clinical indications.
How it works
Neurotrophic signaling: Experimental studies report changes in BDNF, NGF, and pathways involved in synaptic plasticity.
Monoamine systems: Research examines dopaminergic and serotonergic signaling.
Ischemic-stress response: Animal and regional clinical studies have explored neuronal survival and recovery after cerebral ischemia.
Research areas
Neuroprotection models
Learning and memory
Neurotrophic-factor signaling
Cerebral ischemia research
Research / study context
Animal studies: Behavioral, molecular, and ischemia models measure cognition, neurotrophic factors, and neuronal injury.
Regional clinical research: Studies have evaluated neurologic recovery and cognitive outcomes, primarily outside the United States.
Key research findings
Semax has meaningful mechanistic literature but limited large multinational trials.
Most U.S. marketing claims would exceed the strength of the available evidence.
It is not FDA-approved in the United States.
Scientific reference starter set
Peptide Education Hub: Semax profile
PubMed search: Semax BDNF neuroprotection
PubMed search: Semax cerebral ischemia
Research material
View available specifications and batch documentation in the Apex catalog.
Important
For research use only. Not for human consumption. This profile is educational and does not provide treatment or personal-use instructions.